Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glycosylphosphatidylinositol-anchored wall protein 1 (GWT1) is an essential fungal enzyme located in the endoplasmic reticulum that plays a critical role in the early stages of glycosylphosphatidylinositol (GPI) anchor biosynthesis (Source: UniProt P47101). It specifically catalyzes the N-acylation of the inositol ring of glucosaminyl-phosphatidylinositol, a step necessary for the subsequent attachment of proteins to the fungal cell wall (Source: PubMed: 27001387). Because GPI-anchored proteins are vital for maintaining cell wall integrity, adhesion, and biofilm formation, GWT1 serves as a potent target for novel antifungal therapies (Source: PubMed: 31138563). Inhibition of GWT1 leads to the depletion of cell wall proteins, resulting in compromised structural integrity and reduced virulence of various fungal pathogens, including Candida and Aspergillus species (Source: PubMed: 30635339). The most prominent drug targeting this enzyme is manogepix, the active form of the prodrug fosmanogepix, which demonstrates high selectivity for the fungal enzyme over human orthologs (Source: PubMed: 29439114). This selectivity minimizes potential host toxicity, as the human version of the enzyme, PIG-W, is structurally distinct (Source: PubMed: 29439114). This mechanism of action is distinct from existing antifungal classes like azoles or echinocandins, making it effective against many multi-drug resistant strains (Source: PubMed: 31138563). Consequently, GWT1 inhibitors represent a promising new class of antifungals for treating invasive fungal infections (Source: PubMed: 30635339).
Inhibition of GWT1 enzyme activity prevents the acylation of inositol during glycosylphosphatidylinositol (GPI) anchor biosynthesis, leading to defective cell wall assembly and fungal growth inhibition.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glycosylphosphatidylinositol-anchored wall protein 1 (GWT1) (GWT1).